The influence of pretreatment low density lipoprotein cholesterol concentrations on the effect of hypocholesterolemic therapy on coronary atherosclerosis in angiographic trials. Harvard Atherosclerosis Reversibility Project Research Group (Q40421170)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	The influence of pretreatment low density lipoprotein cholesterol concentrations on the effect of hypocholesterolemic therapy on coronary atherosclerosis in angiographic trials. Harvard Atherosclerosis Reversibility Project Research Group	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

1 reference

Europe PubMed Central

The influence of pretreatment low density lipoprotein cholesterol concentrations on the effect of hypocholesterolemic therapy on coronary atherosclerosis in angiographic trials. Harvard Atherosclerosis Reversibility Project Research Group (English)

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

hypocholesterolemia

0 references

atherosclerosis

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

F M Sacks

1

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

C M Gibson

2

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

B Rosner

3

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

R C Pasternak

4

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

P H Stone

5

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

language of work or name

0 references

publication date

1 September 1995

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

American Journal of Cardiology

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

76

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

9

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

78C-85C

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Evaluation of colestipol/niacin therapy with computer-derived coronary end point measures. A comparison of different measures of treatment effect

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980475-5

7 January 2021

Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980475-5

7 January 2021

Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH)

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980475-5

7 January 2021

Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980475-5

7 January 2021

Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS)

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980475-5

7 January 2021

Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS).

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980475-5

7 January 2021

Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980475-5

7 January 2021

Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS)

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980475-5

7 January 2021

Can lifestyle changes reverse coronary heart disease? The Lifestyle Heart Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980475-5

7 January 2021

Regular physical exercise and low-fat diet. Effects on progression of coronary artery disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980475-5

7 January 2021

Effects of intensive multiple risk factor reduction on coronary atherosclerosis and clinical cardiac events in men and women with coronary artery disease. The Stanford Coronary Risk Intervention Project (SCRIP).

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980475-5

7 January 2021

Effect on coronary atherosclerosis of decrease in plasma cholesterol concentrations in normocholesterolaemic patients. Harvard Atherosclerosis Reversibility Project (HARP) Group

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980475-5

7 January 2021

Frequency of low serum high-density lipoprotein cholesterol levels in hospitalized patients with "desirable" total cholesterol levels

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980475-5

7 January 2021

Long-term predictors of subsequent cardiovascular events with coronary artery disease and 'desirable' levels of plasma total cholesterol

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980475-5

7 January 2021

Moderate alcohol intake, increased levels of high-density lipoprotein and its subfractions, and decreased risk of myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980475-5

7 January 2021

Lipid-lowering interventions in angiographic trials

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980475-5

7 January 2021

Natural history of coronary atherosclerosis using quantitative angiography in men, and implications for clinical trials of coronary regression. The Harvard Atherosclerosis Reversibility Project Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980475-5

7 January 2021

Benefits of lipid-lowering therapy in men with elevated apolipoprotein B are not confined to those with very high low density lipoprotein cholesterol

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980475-5

7 January 2021

What benefit can be derived from treating normocholesterolemic patients with coronary artery disease?

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980475-5

7 January 2021

Changes in sequential coronary arteriograms and subsequent coronary events. Surgical Control of the Hyperlipidemias (POSCH) Group

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980475-5

7 January 2021

Prognostic significance of progression of coronary atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980475-5

7 January 2021

Influence of plaque configuration and stress distribution on fissuring of coronary atherosclerotic plaques

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980475-5

7 January 2021

Are we mortgaging the medical profession?

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980475-5

7 January 2021

The pathogenesis of coronary artery disease and the acute coronary syndromes (2).

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980475-5

7 January 2021

Elucidation of the role of plaque instability and rupture in acute coronary events

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980475-5

7 January 2021

Rationale and design of a secondary prevention trial of lowering normal plasma cholesterol levels after acute myocardial infarction: The cholesterol and recurrent events trial (CARE)

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980475-5

7 January 2021

Baseline characteristics in the Cholesterol and Recurrent Events (CARE) trial of secondary prevention in patients with average serum cholesterol levels

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980475-5

7 January 2021

Cholesterol and Recurrent Events: a secondary prevention trial for normolipidemic patients. CARE Investigators.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980475-5

7 January 2021

Identifiers

10.1016/S0002-9149(99)80475-5

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40421170&oldid=1897329391"